Did You Know?

Editor’s Picks

Latest News

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

First patient dose in the Phase 1/2 clinical trial expected in mid-2023BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics,...

Beyond Cancer™ Presents Positive Preclinical Data for Ultra-High Concentration Nitric Oxide (UNO) Therapy in Solid Tumors During the American Association for Cancer Research (AACR) 2023 Annual Meeting

error: Content is protected !!